GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Probability of Financial Distress (%)

Journey Medical (Journey Medical) Probability of Financial Distress (%) : 0.30% (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Journey Medical's Probability of Financial Distress (%) is 0.30%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Journey Medical's Probability of Financial Distress (%)

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Journey Medical's Probability of Financial Distress (%) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Journey Medical's Probability of Financial Distress (%) falls into.



Journey Medical Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-5.82

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.30%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Journey Medical  (NAS:DERM) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Journey Medical Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Journey Medical's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus